Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street
Get Alerts SOMX Hot Sheet
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q4 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.42 million.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Eyenovia Inc (EYEN) Misses Q4 EPS by 1c
- Singular Genomics Systems, Inc. (OMIC) Reports In-Line Q4 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!